Kinnate Biopharma Inc.

39 articles with Kinnate Biopharma Inc.

• Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study

  11/1/2021

  Kinnate Biopharma Inc. today announced a collaboration with Guardant Health, a leading precision oncology company, focused on characterizing the prevalence of patients with advanced solid tumors bearing BRAF Class I, II and III alterations.

• Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer

  10/28/2021

  Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that the company’s Chief Scientific Officer, Eric Murphy, Ph.D., will step down from that role on December 3, 2021 to pursue a new opportunity.

• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference

  10/7/2021

  Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, will be presenting design and rationale details of a Phase 1 trial evaluating KIN-2787 during the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

• Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference

  9/30/2021

  Kinnate Biopharma Inc. announced that details of the trial design and scientific rationale for its first in human Phase 1/1b trial evaluating KIN-2787 has been selected for a poster presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021.

• Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference

  9/13/2021

  Kinnate Biopharma Inc. announced results from preclinical studies evaluating its lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248.

• 

  Cardior Raises $76 Million to Advance Heart Failure Treatment

  8/25/2021

  Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.

• Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results

  8/16/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021.

• Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

  7/7/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the William Blair Biotech Focus Conference 2021,

• Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors

  6/28/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the appointment of Helen Sabzevari, Ph.D. to its Board of Directors.

• Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires

  6/7/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), today announced the appointment of Neha Krishnamohan as Chief Financial Officer and Executive Vice President

• Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

  6/4/2021

  Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations

• Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference

  5/25/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Nima Farzan, Chief Executive Officer of Kinnate, will provide a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually from June 8-11, 2021.

• 

  FDA Receives Slew of New Drug Applications for Bipolar Disorder, Opioid Disorder and Rare Disease

  5/19/2021

  Several biopharmaceutical companies have submitted NDAs to the U.S. FDA covering treatment indications ranging from an opioid overdose, bipolar disorder and rare disease.

• Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787

  5/17/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the U.S Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KIN-2787 and also announced financial results for the quarter ended March 31, 2021.

• 

  Interline Will Focus $92 Million Investment to Advance Precision Medicine Platform

  5/14/2021

  Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.

• Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

  5/13/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of a $35 million Series A financing for a joint venture in China.

• Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

  5/10/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that data from pre-clinical studies of its RAF inhibitor candidate,

• Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors

  4/30/2021

  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Dr. Stephen Kaldor, one of the company’s co-founders, is not being nominated for re-election to the company’s Board of Directors when his term expires at the company’s 2021 annual meeting